Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BeyondSpring Inc | BYSI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.27 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.6534 - 4.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 2.27 | USD |
BeyondSpring Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
88.35M | 38.92M | - | 1.35M | -33.28M | -0.86 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BeyondSpring News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BYSI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.80 | 2.50 | 1.80 | 2.21 | 76,091 | 0.47 | 26.11% |
1 Month | 3.54 | 3.61 | 1.76 | 2.48 | 99,966 | -1.27 | -35.88% |
3 Months | 1.01 | 4.00 | 0.9701 | 2.78 | 238,112 | 1.26 | 124.75% |
6 Months | 1.12 | 4.00 | 0.7777 | 2.46 | 134,261 | 1.15 | 102.68% |
1 Year | 0.9998 | 4.00 | 0.6534 | 2.00 | 98,825 | 1.27 | 127.05% |
3 Years | 10.23 | 33.00 | 0.542 | 13.34 | 670,294 | -7.96 | -77.81% |
5 Years | 14.33 | 33.00 | 0.542 | 13.30 | 457,729 | -12.06 | -84.16% |
BeyondSpring Description
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. |